Navigation Links
Mayo Clinic Proceedings: Gabapentin opens window of communication
Date:6/16/2010

ROCHESTER, Minn. -- For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

In the June issue of Mayo Clinic Proceedings, researchers from Italy describe four patients with locked-in syndrome who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). Because these patients' eyes spontaneously and continuously oscillated in a variety of directions beyond their control, they could no longer interact with family members, physicians or other people.

The lead author, Francesca Pistoia, M.D., University of L'Aquila, Italy, reports that a decision was made to treat these patients with daily continuous gabapentin therapy based on a previous successful experience. Gabapentin was started as a single 300 mg dose on the first day followed by 600 milligrams per day in divided doses on the second day. In two of the patients, this dosage reduced ocular symptoms, and communication and quality of life improved. For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.

In all four patients, attempts to stop treatment resulted in recurrence of dancing eye symptoms six hours after the last dose. Thus, gabapentin use was promptly resumed. Researchers found none of the patients experienced adverse effects from the treatment.

In an accompanying editorial, Joseph Sirven, M.D., Mayo Clinic neurologist, discusses the off-label use of gabapentin, which was approved by the U.S. Food and Drug Administration in 1994 for use as an adjunctive medication to control partial seizures. Dr. Sirven writes, "Ironically, despite the fact that the drug was invented and synthesized for its use in seizure prevention, its smallest market today is epilepsy and seizures."

"The study by Pistoia and colleague
'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Free Clinics Play Important Role for Uninsured in U.S.
3. Sunrise Services Wins the Gold in Medisoft Clinical Sales Contest
4. Sanford Health Announces Sanford Children's Clinic in Klamath Falls, OR
5. Sharron Davies opens new respiratory research clinic
6. European patient survey add weight to expert call for greater clinical consensus on BTCP
7. FDA approves first human neural stem cell clinical trial to treat brain tumors
8. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
9. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
10. Fox Chase clinical trial tests first of its kind antibody
11. Launching Five Clinics on Wheels This Year, Ronald McDonald House Charities Celebrates Ten Years of the Ronald McDonald Care Mobile Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 TheCelebrityDresses.com, a popular ... big discounts on their summer fashion cocktail dresses. The ... short dresses that would be suitable for a wide ... , TheCelebrityDresses.com designs and make high quality trendy ... they use include high quality satin, chiffon and cotton. ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... a study from the RSSearch® Patient Registry evaluating ... body radiotherapy (SBRT) for the treatment of centrally ... lung metastases. , The study, published in ... http://www.ro-journal.com/content/10/1/113/abstract ), included 111 patients with 114 centrally ...
(Date:6/2/2015)... Robert LaPrade, MD, PhD, Colorado Knee ... Research Institute, participated in the study “ When ... This was a collaborative project from the American Orthopaedic ... recently published in the American Journal of Sports Medicine. ... is evidence that early sport specialization may put young ...
(Date:6/2/2015)... Each year, Cosmetic Executive Women (CEW) awards ... year, the organization’s members – 8,000 industry experts – ... Beauty Quest Award at the 2015 Beauty Insiders’ Choice ... and 2-in-1 approach to skincare differentiated it amongst a ... consumer and professional fan bases, QVC has awarded Scalisi ...
(Date:6/2/2015)... 2015 SB 277 (CA Legislature, bit.ly/1Q0P8OY) ... to attend public or private school. SB277 cleared three ... the Appropriations Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). ... , “We believe that this bill affects the ... than it will (the) affect public health of California.. ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2
... 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC ... pharmaceutical, medicinal and diagnostic products in China,today announced ... to,the Company,s Form 10KSB for the year 2006. ... Form 10QSB for the three, six and nine ...
... COMPANY REPORTS PROGRESS ON KEY INITIATIVES, RANCHO CORDOVA, ... a leading supplier of innovative products and,services that process, ... treatment of disease and injury, today reported results for,the ... quarter ended September 30, 2007, were $3.6 million,compared with ...
... OWINGS MILLS, Md., Nov. 8 Medifast, Inc.,(NYSE: ... the period ended,September 30, 2007. For quarter-ended September 30, ... from $19.6 million in the third,quarter of 2006. The ... share ($0.07 per diluted share), versus $1,455,000 or $0.11 ...
... ESAs can increase cancer growth, cause stroke and heart ... News) -- The U.S. Food and Drug Administration on ... erythropoiesis-stimulating agents, which are drugs used to treat certain ... Aranesp, Epogen and Procrit, and detail their dangers to ...
... N.J., Nov. 8 Wyeth (NYSE: WYE ),announced ... First Boston,Healthcare Conference on Tuesday, November 13, 2007 at ... M. Mahady, Senior Vice President,Wyeth and President, Wyeth Pharmaceuticals ... for investors at, http://www.wyeth.com and available for replay ...
... CLEVELAND, Nov. 8 Medical Mutual and Ohio ... to provide quality,affordable health insurance to OFBF,s more ... Farm Bureau members will gain access to,Medical Mutual,s ... hospitals and other medical service providers in Ohio. ...
Cached Medicine News:Health News:China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 3Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 4Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 5Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 6Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 2Health News:Medifast Announces Third-Quarter 2007 Results 3Health News:Medifast Announces Third-Quarter 2007 Results 4Health News:Medifast Announces Third-Quarter 2007 Results 5Health News:Medifast Announces Third-Quarter 2007 Results 6Health News:Medifast Announces Third-Quarter 2007 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 8Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3
(Date:6/1/2015)... DUBLIN , June 1, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/qrmgrq/_analysis_of_the ) has announced the addition of ... Image Displays Market" report to their ... ,This report provides an in-depth analysis of ... revenue forecast, market shares, market dynamics, and ...
(Date:6/1/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced data ... in a Phase 1 investigator-sponsored study at the University ... presented at the 2015 American Society of Clinical Oncology ... Results from this study show a tolerable safety ... given intravenously.  Based in part on the ...
(Date:6/1/2015)... June 1, 2015 The Middle Eastern MRI systems ... which is replacing CT because of its higher sensitivity and ... one between the two available systems of MRI, open and ... top and bottom and do not enclose the patient in ... a study which shows that one in every 6 patients ...
Breaking Medicine Technology:Analysis of the US Medical Image Displays Market 2015-2017 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Middle East Open System MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2
... the,symptoms of thyroid disease for another disorder such ... a new edition of a report from,Harvard Medical ... particularly in older men and women, that doctors ... focus on common,illnesses that occur with age, according ...
... /Xinhua-PRNewswire/ -- TaiGen Biotechnology,Inc. announces the successful completion ... clinical trial of Nemonoxacin (TG-873870) for,the treatment of ... have been admitted to the trial. Completion of ... quarter of 2007. In this trial, the effect,of ...
Cached Medicine Technology:You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report 2TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP) 2
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Pocket-sized instrument with fiber optic illumination. Swivelling viewing window with 3X magnification....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: